The need for developing alternative melanoma treatment options {#S1}
==============================================================

Malignant melanoma is a devastating disease with historically poor prognosis. For the first time, several drugs provide a significant improvement in overall survival of these patients ([@R25]; [@R51]; [@R58]; [@R93]). These drugs fall into two categories: they either block the MAPK signaling pathway in BRAF^V600E^ mutated melanoma, or they alter the patient's own immune system to attack melanoma. Pathway-targeting drugs include BRAF inhibitors that specifically target the BRAF^V600E^ mutation (vemurafenib and dabrafenib), or MEK inhibitors (trametinib and cobimetinib), either alone or in combination ([@R26]). Recent clinical trials with the combinations of both BRAF and MEK inhibitors showed improvements in progression-free survival compared to a single inhibitor in BRAF^V600E^ melanoma patients, but also with increased side effects in some cases ([@R49]; [@R52]; [@R53]). Although these treatments lead to a quick initial response, for instance \~ 50% of patients respond to vemurafenib, responses are not durable ([@R7]). Most patients eventually relapse, and the intrinsic or acquired resistance mechanisms include reactivation of MAPK signaling through alternative pathways, or activation of other oncogenic pathways such as PI3K/AKT ([@R6]; [@R24]). In addition, patients without the BRAF^V600E^ mutation do not benefit from these treatments.

For immunotherapy, the humanized monoclonal antibodies ipilimumab and pembrolizumab block the negative regulators of immune responses, thereby stimulating T-cell response against melanoma ([@R22]; [@R34]). Ipilimumab targets CTLA-4 ([@R39]) and pembrolizumab targets PD-1 ([@R79]). Efficacy with ipilimumab is longer than with BRAF/MEK inhibitors, but response rate is poor at only 10--15% ([@R39]). A distinct genetic landscape of neoantigens is reported to be present in melanomas with a strong response to ipilimumab ([@R87]). Moreover, both antibodies lead to significant immune-mediated side effects ([@R25]), and relapse rate is not yet known for pembrolizumab. Therefore, many patients do not respond to current therapies, and there is still a pressing need to develop alternative treatment options for metastatic melanoma, especially for those with wild-type BRAF.

Human tumors are composed of heterogeneous cell populations. Tumor heterogeneity is implicated in tumor cells' resistance to treatment, and may be explained by several models. The stochastic (clonal evolution) model states that every cell within a tumor has similar tumorigenic and self-renewing potential. These cells evolve and lead to heterogeneity, through clonal expansion with acquired genetic and epigenetic changes over time ([@R33]; [@R67]; [@R83]). This process is influenced by extrinsic factors including therapies. In contrast, the hierarchical model states that only a subpopulation of tumor cells, cancer stem cells (CSCs), possess self-renewal capacity and contribute to intra-tumoral heterogeneity by giving rise to non-CSCs within the same tumor ([@R16]; [@R27]; [@R63]; [@R78]). This model suggests eliminating CSCs will help eradicating tumors. Cancer cell plasticity also contributes to tumor heterogeneity by mechanisms such as phenotype-switching. Cells may switch among proliferative, invasive and stem cell-like states in response to microenvironments ([@R9]; [@R10]; [@R40]; [@R41]). Moreover, a dynamic process mediated by a temporarily distinct subpopulation may also contribute to melanoma heterogeneity ([@R81]). These models/mechanisms are not mutually exclusive. The CSC populations themselves are heterogeneous and dynamic, and may evolve through clonal evolution or display phenotype-switching ([@R50]; [@R64]). In melanoma, the high mutation load also likely contributes to heterogeneity. Interestingly, wild-type BRAF/NRAS melanomas seem to have a higher mutation load than mutant BRAF/NRAS tumors ([@R56]).

To prevent relapse, it is proposed that effective therapy needs to eradicate all subpopulations of tumor cells, killing the mass of cancer cells (de-bulking) as well as any resistant subpopulations such as CSCs ([@R36]). One known cancer resistance mechanism is the dysregulation of BCL-2 family members, and recent studies indicate that this also contributes to the survival of CSCs. This review provides an overview of developing new melanoma treatments by targeting BCL-2 dysregulation with the purpose of de-bulking melanomas and eliminating drug-resistant subpopulations of CSCs in melanoma. We include the rationale, methods used, and current promising approaches.

The regulation of apoptosis by the BCL-2 family {#S2}
===============================================

The BCL-2 family of proteins plays a crucial role in regulating intrinsic or mitochondrial apoptosis ([@R18]). The members are divided into three groups based on their functions and structures: **1)** anti-apoptotic proteins (also called inhibitors), which include BCL-2, BCL-X~L~, BCL-W, MCL-1, A1, and BCL-B; **2)** multi-BH domain pro-apoptotic proteins (also called effectors), which include BAX and BAK; **3)** and BH3-only pro-apoptotic proteins (also called activators or enhancers), which include NOXA, BIM, BID, BAD, BMF, BIK and others ([Figure 1a](#F1){ref-type="fig"}). Upon activation, the effectors (BAX/BAK) oligomerize, triggering cytochome C release from the mitochondria and apoptosome activation, and finally result in caspase-9-dependent apoptosis ([@R18]). Anti-apoptotic proteins bind to BAX/BAK, preventing their activation. The balance of the interactions between different BCL-2 family members determines whether cells will initiate apoptosis ([@R14]; [@R61]). Some BH3-only members only bind to one group of inhibitors, e.g., NOXA only binds to MCL-1/A1. Others can bind to multiple inhibitors, such as BIM, PUMA, and tBID.

BAX/BAK oligomerization is necessary for activation of apoptosis, and the activation has been proposed to be direct or indirect ([@R18]). In the direct activation model, the BH3-only proteins directly bind to effectors (BAX/BAK) leading to activation. In the indirect model, binding of BH3-only proteins to the inhibitors releases the effectors BAX/BAK, allowing for activation. In the indirect model, apoptosis only occurs when all the anti-apoptotic members are neutralized. These two models are not mutually exclusive; one may be more dominant than the other, dependent on the circumstances. Nevertheless, in both models, the binding of BH3-only proteins to anti-apoptotic members can activate effectors and induce apoptosis ([@R18]). Thus, mimicking the pro-apoptotic BH3-only proteins by small molecules is a logical approach to develop cancer drugs ([@R3]; [@R61]; [@R65]).

The rationale to target BCL-2 family members in melanoma {#S3}
========================================================

Dysregulation of BCL-2 family proteins occurs frequently, and plays a major role in conferring resistance to cell death in many cancers, including melanoma ([@R66]; [@R71]). Importantly, many BCL-2 proteins are downstream of the commonly activated signaling pathways RAS/BRAF/MAPK and PI3K/AKT ([Figure 1a](#F1){ref-type="fig"}) ([@R35]; [@R45]). For instance, oncogenic BRAF^V600E^ suppresses apoptosis by upregulating anti-apoptotic MCL-1 ([@R35]; [@R57]). Also, through phosphorylation, constitutively activated RAS/BRAF/MAPK signals down-regulate or inactivate pro-apoptotic BAD ([@R23]) or BIM ([@R32]). Thirdly, activated PI3K/AKT signals inhibit cell death by inactivating BAD's ability to bind BCL-2 or BCL-XL ([@R20]; [@R88]) or down-regulating transcription of pro-apoptotic members BIM and PUMA through sequestering the transcription factors FOXOs away from their promoters ([@R101]). Activated AKT also prevents induction of pro-apoptotic BIM-EL and BMF upon BRAF inhibition, contributing to melanoma resistance to BRAF inhibitors ([@R85]) ([Figure 1a](#F1){ref-type="fig"}). Moreover, gene amplification results in up-regulation of anti-apoptotic BCL2A1 in some melanoma ([@R37]). Furthermore, the melanocyte-specific transcription factor (microphthalmia-associated transcription factor, MITF) is amplified in a subset of melanoma which can upregulate BCL-2 and contribute to resistance to cell death ([@R38]).

The effects of BRAF inhibitors in melanoma are dependent on the induction of BH3-only protein BIM and BMF ([@R85]); BIM repression by epigenetic chromatin remodeling ([@R86]) contributes to melanoma resistance to BRAF inhibition. Considering that some BCL-2 family members are regulated by MAPK or PI3K/AKT signaling and that activation of these pathways contributes to relapses from treatment of BRAF inhibitor, targeting downstream apoptotic proteins may be alternative options to overcome relapse. Indeed, the BAD-mimetic, ABT-737, has been shown to overcome AKT-mediated resistance to BRAF inhibition ([@R70]).

Taken together, multiple mechanisms lead to dysregulation of the BCL-2 family, and this likely contributes to melanoma development of resistance to current treatments ([Figure 1a](#F1){ref-type="fig"}). Thus targeting the BCL-2 family is an alternative way to combat melanoma, independent of BRAF mutation status, and overcome melanoma relapse from current treatments.

De-bulking Cancer cells by targeting BCL-2 family members {#S4}
=========================================================

Single Agents targeting BCL-2 or MCL-1 {#S5}
--------------------------------------

Early attempts at targeting BCL-2 family members included antisense, single-chain antibodies, ribozymes, BH3 peptides and hydrocarbon stapling. However, most failed, possibly due to poor delivery systems and the short-term stability of the compounds (see review ([@R92]). Current more successful approaches focus on stable small molecule inhibitors (SMI), called "BH3 mimetics", which mimic the pro-apoptotic BH3-only proteins to induce apoptosis in cancer cells ([Table 1](#T1){ref-type="table"}).

Currently ABT-263 (navitoclax) and ABT-199 are in clinical trials, with encouraging preliminary results ([@R30]; [@R80]; [@R98]). ABT-263, an oral version of ABT-737, is a mimetic of BH3-only BAD that inhibits BCL-2, BCL-XL and BCL-W, but not MCL-1 ([@R68]; [@R94]; [@R95]). ABT-199 was modified from ABT-263, with a sub-nano-molar affinity for BCL-2 but not BCL-XL ([@R21]). Unfortunately, single agent treatment of melanoma with ABT-737/ABT-263 is not effective, with MCL-1 as the main contributor of resistance ([@R13]; [@R54]; [@R60]).

MCL-1 overexpression is linked to the pathogenesis of multiple cancers, including melanoma ([@R5]; [@R44]; [@R57]; [@R91]). Many groups are developing SMIs that target MCL-1 with the aim of overcoming cancer resistance to ABT-737/263. Promising compounds include Maritoclax, WP1130, UMI-77, Clitocine and Compound 11, with some efficacy in animal studies ([@R2]; [@R72]; [@R89]; [@R97]). However, clinical trials are still needed ([Table 1](#T1){ref-type="table"}).

Combination Therapy {#S6}
-------------------

As mentioned above, targeting a single BCL-2 family member is not sufficient to kill melanoma. In addition, therapeutics with single molecular targets often fails due to the heterogeneity and dynamic nature of cancer cells. Thus, utilizing combination therapies is an emerging strategy to treat cancer. Combination therapy increases the number of cells responding to treatment, decreases the possibility of drug resistance, kills heterogeneous populations of cells within the tumor, and may also lower side-effects.

Several combination strategies target BCL-2 family members, with promising pre-clinical evidence ([Table 1](#T1){ref-type="table"}). As mentioned earlier, MCL-1 is the main mediator of melanoma resistance to BCL-2 inhibitors such as ABT-737, and NOXA is a pro-apoptotic BH3-only protein that inhibits MCL-1. Therefore, inhibiting BCL-2, combined with either inhibition of MCL-1 or activation of NOXA, is effective at killing melanoma([@R54]; [@R60]; [@R62]; [@R76]; [@R77]). Another strategy is sensitizing melanoma with BCL-2 SMIs, coupling with molecular-targeted agents such as BRAF inhibitors ([@R99]). The last strategy combines BCL-2 SMIs with immune therapies, again using BH3 mimetics such as ABT-737, to sensitize tumor cells to immunotherapies ([@R1]; [@R43]). All these approaches provide treatment opportunities that may limit escape mechanisms in different patients and enhance the possibilities for personalized cancer medicine approach to treatment. Although the above strategies are promising, none explored the effectiveness of specifically eradicating resistant subpopulations, which is an important contributor for melanoma resistance.

Cancer Stem Cells (CSCs) in melanoma {#S7}
====================================

CSCs are defined as a subpopulation of cancer cells which possess two essential stem-cell functions: self-renewal and differentiation ([@R16]). CSCs enhance cancer initiation, progression, metastasis, and chemo-resistance ([@R16]; [@R63]; [@R69]). CSCs also contribute to intra-tumoral heterogeneity, with their ability to give rise to non-CSCs within the same tumor ([@R27]; [@R69]). To prevent relapse, targeting CSCs should be an important part of treatment strategies.

The gold standard method to confirm the existence of CSCs is to detect their capacity to self-renew and differentiate, using *in vivo* serial xenotransplantation assays ([@R16]). Recently, several lineage tracing studies with genetically engineered mouse models provided further evidence for the existence of CSCs ([@R69]). To date, CSCs have been identified in many cancers ([@R69]; [@R90]).

Quintana and colleagues reported a high frequency of tumor-initiating cells (TICs) in human melanoma using highly permissive conditions, raising questions on the existence of CSCs in human melanoma ([@R73]). However, TICs are not the same as CSCs with self-renewal and differentiation capacity ([@R84]), and the high frequency of TICs does not disprove the presence of CSCs (see reviews ([@R48]; [@R50]; [@R64]; [@R84])). Rather, Quintana's papers simply suggest that TICs are influenced by many experimental factors. Indeed, when using the gold standard *in vivo* assays, numerous groups have detected subpopulations of melanoma cells that fulfill the criteria for CSCs ([@R48]; [@R50]; [@R64]; [@R84]), and these cells are associated with tumor progression and chemoresistance.

Several melanoma stem cell (MSC) markers have been suggested in peer-reviewed literatures, and these include cell surface markers ABCB5 ([@R82]) and CD271 ([@R4]; [@R15]; [@R75]), and activity of ALDH (a detoxifying enzyme) ([@R55]). ABCB5 belongs to the ATP-binding cassette (ABC) transporter superfamily, implicated in multidrug resistance. CD271 is a nerve growth factor receptor, and is also a marker of mesenchymal stem cells ([@R96]) and hypopharyngeal CSCs ([@R42]). However, recent evidence suggests that not all CD271+ cells are the same, and only the slow growing CD271+ population displays a high tumorigenic potential and stemness ([@R8]). In addition, knockdown of CD271 alone decreases, but does not prevent, the accumulation of the stress-induced drug resistant cell population ([@R59]). These recent data suggest that CD271 may be an imperfect MSC marker.

In sum, subpopulations of melanoma cells possess characteristics of CSCs (tumorigenesis with self-renewal and differentiation capacities), with enhanced ability for melanoma initiation, maintenance, and resistance to treatments. Although various markers can enrich MSCs, the most critical functional trait of these subpopulations is their self-renewal capacity for long-term growth of melanoma. Therefore self-renewability of these subpopulations should be targeted to prevent relapse after treatment.

Eradicating CSCs by targeting BCL-2 family members {#S8}
==================================================

Ideally, cancer treatments should eliminate both non-CSCs (the bulk of the tumors) and CSCs ([@R27]; [@R74]). Utilizing combination therapy is likely the best strategy for targeting all subpopulations in heterogeneous tumors, and promising new drugs should test the efficacy of killing CSCs.

Potential strategies that focus on CSCs include differentiating CSCs into mature cells with no self-renewal capacity, eliminating CSCs by targeting essential pathways, or disrupting their niche. A successful example of differentiation therapy is the use of all-trans retinoic acid on acute promyelocytic leukemia patients to differentiate the cancer cells into mature granulocytes ([@R69]). Another approach to kill CSCs is through targeting their dependent signaling pathways, such as NOTCH, ABC cassettes, NF-κB, TGF-β, WNT, and JAK-STAT ([@R12]; [@R69]). In addition, tumor microenvironment may serve as CSC's niche and can also be a drug target to eliminate CSCs. For example, angiogenesis is crucial in maintaining tumor niches, and the melanoma niche encompasses a network consisting of not only endothelial-lined blood vessels, but also "vasculogenic mimicry" channels formed by melanoma cells ([@R47]). Drugs targeting angiogenesis (such as VEGF inhibitors) can disrupt tumor niche and indirectly eradicate CSCs ([@R28]; [@R50]; [@R69]; [@R82]).

Numerous recent studies show that CSCs are especially vulnerable to SMIs targeting the BCL-2 family. Lagadinou *et al* showed BCL-2 was overexpressed in quiescent leukemia stem cells (LSCs) with low levels of ROS, and BCL-2 inhibitor ABT-263 selectively eradicated the LSCs ([@R46]). In bone-marrow-resident human LSCs, splice-isoform switching favored expression of multiple pro-survival BCL-2 members, and a pan-BCL-2 inhibitor sensitized them to tyrosine kinase inhibitors ([@R31]). Other CSCs, such as breast and colon CSCs, displayed upregulated BCL-2 ([@R29]). BCL-XL overexpression contributed to survival of colon CSCs ([@R17]) and lung CSCs ([@R100]). When treated with ABT-737 but not ABT-199, these cells died ([@R100]) or were sensitized to chemotherapies ([@R17]). Furthermore, suppressing MCL-1 may overcome the tumor-plasticity-induced drug resistance in multiple myeloma cells ([@R19]). These findings highlight that inhibition of pro-survival BCL-2 family proteins is a promising approach to target chemotherapy-resistant CSCs and plasticity of tumors.

To our knowledge, few studies explored the BCL-2 family members as targets for eradicating heterogeneous melanomas or MSCs. Recently we identified the combination of a BCL-2 Inhibitor with the retinoid derivative fenretinide as a promising treatment, for both wild-type and mutant BRAF cells, and for non-MSCs and MSCs ([@R62]) ([Figure 1b](#F1){ref-type="fig"}). The combination synergistically inhibited melanoma growth *in vitro* and *in vivo*, disrupted melanoma spheres, decreased the percentage of ALDH^high^ cells and inhibited the self-renewal capacity of MSCs. These effects were observed in melanoma cells with mutations of either BRAF or NRAS. Interestingly, single drug treatments increased characteristics of MSCs for some melanoma samples, and only the combination treatment significantly reduced the self-renewal capacity of MSCs in all the samples tested. Proliferation stopped post-treatment, with no re-growth of tumor cells. The mechanism of action for the combination involves antagonizing multiple anti-apoptotic BCL-2 members at once ([@R62]) ([Figure 1b](#F1){ref-type="fig"}). These results support the idea that combination treatments are more potent to eliminate MSCs or other resistant subpopulation and targeting multiple pro-survival BCL-2 family members is a promising approach for melanoma ([Figure 1b](#F1){ref-type="fig"}).

Summary {#S9}
=======

By killing heterogeneous tumors and eliminating drug-resistant subpopulations, SMIs, targeting multiple BCL-2 family members, provide an option for melanoma, especially the wild-type BRAF melanomas. This approach thus offers an alternative way to combat melanoma and may help achieve longer lasting treatment effects.
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![Targeting the BCL-2 family as a treatment option for melanoma\
(a) A simplified illustration for the rationale to target BCL-2 family members in melanoma. Green box represents the pro-apoptotic proteins, and red box represents the anti-apoptotic proteins. Multiple BCL-2 proteins are downstream of the RAS/BRAF/MAPK and PI3K/AKT signaling pathways, the commonly activated pathways in melanoma. The activation of these pathways leads to the dysregulated expression of multiple BCL-2 proteins, and likely contributes to resistance to cell death in melanoma. For instance, the activated RAS/BRAF/MAPK signal upregulates MCL-1 and blocks BIM and BAD (see text for details). Thus, targeting the BCL-2 family may provide an alternative way to combat melanoma regardless of its BRAF status, and to overcome melanoma relapse from current treatments. (b) Combination therapy debunks and kills the MSCs. The various blue cells represent heterogeneous non-MSCs populations, and the yellow cells represent the MSC populations. Standard therapy may be successful in debulking melanoma cells initially. However, it fails to kill MSCs, resulting in tumor relapse due to the self-renewal capacity of MSCs. The combination therapy targeting multiple BCL-2 anti-apoptotic members debulks and kills the MSCs, preventing future relapse of melanoma.](nihms677960f1){#F1}

###### 

Examples of SMIs targeted BCL-2 family members in clinical trials or pre-clinical studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SMI                           Target(s)                                                  Clinical Trials or Pre-Clinical studies                                                       
  ----------------------------- ---------------------------------------------------------- ----------------------------------------- --------------------------------------------------- ---------
  **Gossypol**                  BCL-2\                                                     Adrenocortical carcinoma                  N/A                                                 II
                                BCL-XL\                                                                                                                                                  
                                MCL-1\                                                                                                                                                   
                                BCL-W\                                                                                                                                                   
                                BCL-B                                                                                                                                                    

  Lymphoma                      Paclitaxel, carboplatin                                    I                                                                                             

  Advanced SCLC, solid tumors   Cisplatin, etoposide                                       I                                                                                             

  Advanced prostate cancer      Bicalutamide                                               II                                                                                            

  **Obatoclax**                 BCL-2\                                                     Advanced SCLC                             Carboplatin, etoposide                              I/II
                                MCL-1\                                                                                                                                                   
                                BCL-XL\                                                                                                                                                  
                                BCL-W\                                                                                                                                                   
                                BCL-B\                                                                                                                                                   
                                BFL-1                                                                                                                                                    

  AML                           N/A                                                        II                                                                                            

  CLL                           N/A                                                        I/II                                                                                          

  Hodgkins lymphoma             N/A                                                        II                                                                                            

  MCL, Lymphoma                 Bortezomib                                                 I/II                                                                                          

  NSCLC                         Docetaxel                                                  I/II                                                                                          

  SCLC                          Topotecan hydrochloride                                    I/II                                                                                          

  **ABT-263 (ABT-737)**         BCL-2\                                                     CLL, SCLC, Leukemia                       N/A                                                 II,I,II
                                BCL-XL\                                                                                                                                                  
                                BCL-W                                                                                                                                                    

  Lymphoma, CLL, solid tumors   Ketoconaxole                                               I                                                                                             

  CLL                           Fludarabine, Cyclophosphomide, Rituximab                   I                                                                                             

  Solid tumors                  Doxetaxel, Gemcitabine, Etoposide, Cisplatin, Paclitaxel   I                                                                                             

  Lymphoma; CLL                 Rifampin                                                   I; II                                                                                         

  **ABT-199**                   BCL-2                                                      SLL, NHL, CLL, AML                        N/A                                                 I; II

  B-cell Lymphoma               Rituximab                                                  IB                                                                                            

  **Maritoclax**                MCL-1                                                      Melanoma                                  Single and with ABT-737; *In vitro* and *In vivo*   N/A

  AML                           Single; *In vitro*                                                                                                                                       

  **Clitocine**                 MCL                                                        hepatocellular carcinoma                  Single; *In vitro* and *In vivo*                    N/A

  **UMI-77**                    MCL                                                        Pancreatic cancer                         Single; *In vitro* and *In vivo*                    N/A
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The information for clinical trials is adapted from [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

**Abbreviations:** AML -- acute myeloid leukemia, CLL -- chronic lymphocytic leukemia, MCL -- mantle cell lymphoma, NSCLC -- non-small cell lung cancer, NHL -- non-Hodgkins lymphoma, SCLC --small cell lung cancer, SLL -- small lymphocytic leukemia, N/A--not available

**Note:** None of the MCL-1 inhibitors listed is in clinical trials yet, thus we provided the information on preclinical studies for these instead. More details can be found in reviews ([@R2]; [@R3]).
